Welcome to our dedicated page for Soleno Therapeutics news (Ticker: SLNO), a resource for investors and traders seeking the latest updates and insights on Soleno Therapeutics stock.
Soleno Therapeutics develops and commercializes novel therapeutics for rare diseases, centered on VYKAT XR (diazoxide choline) extended-release tablets for hyperphagia in adults and children 4 years and older with Prader-Willi syndrome. News about SLNO commonly covers the U.S. commercial launch of VYKAT XR, operating and financial results, prescriber and patient-access metrics, and clinical publications tied to the DCCR development program.
Company updates also include regulatory matters for diazoxide choline, corporate finance actions, executive and governance changes, investor conference participation, and securities-litigation notices involving product-safety and disclosure allegations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.